AstraZeneca (AZN) Shares Plunge After MYSTIC Trial Did Not Meet Primary Endpoint
Tweet Send to a Friend
AstraZeneca (NYSE: AZN) shares are plunging 16% in pre-open trade after the company announced progression-free survival (PFS) results for the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
